// App-Quantinova.ai

: A Phase I Trial of iPSC-Derived MSCs (CYP-001) in Steroid-Resistant Acute GvHD

Researchers

Presenter

  • Adrian Bloor

Principal Investigators

  • Amit Patel

  • James E Griffin

  • Maria H Gilleece

  • Rohini Radia

  • David T Yeung

  • Igor Slukvin

  • Kilian Kelly

  • John E.J. Rasko

Medical Centers

  • Haematology and Transplant Unit, The Christie NHS Foundation Trust, Manchester, United Kingdom

  • Stem Cell Transplantation and Cellular Therapy Unit, Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom

  • University of Liverpool, Liverpool, United Kingdom

  • Adult Bone Marrow Transplant, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom

  • Department of Histopathology, Leeds Teaching Hospitals NHS Foundation Trust, Leeds, United Kingdom

  • Department of Haematology, Nottingham City Hospital, Nottingham, United Kingdom

  • School of Medicine, University of Adelaide, Adelaide, Australia

  • Department of Haematology, Institute of Medical Veterinary Science, Adelaide, Australia

  • Department of Cell and Regenerative Biology, University of Wisconsin, Madison, WI

  • Cynata Therapeutics Limited, Carlton, Australia

  • Royal Prince Alfred Hospital, Camperdown, Sydney, Australia

Locations

  • United Kingdom

  • Australia

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Graft-versus-host disease

Biomarkers

  • Mesenchymal stem cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT02923375

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved